Selecta Biosciences (NASDAQ:SELB) Stock Price Up 19.4%

Shares of Selecta Biosciences Inc (NASDAQ:SELB) rose 19.4% during mid-day trading on Thursday . The company traded as high as $1.85 and last traded at $2.15, approximately 6,117 shares traded hands during mid-day trading. A decline of 96% from the average daily volume of 143,584 shares. The stock had previously closed at $1.80.

SELB has been the topic of a number of analyst reports. ValuEngine raised Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday. Mizuho reaffirmed a “buy” rating and issued a $4.00 price target on shares of Selecta Biosciences in a research report on Friday, May 10th. Finally, Zacks Investment Research lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $8.04.

The firm has a market capitalization of $86.45 million, a price-to-earnings ratio of -0.71 and a beta of 1.17. The company has a 50-day moving average price of $1.82.

Selecta Biosciences (NASDAQ:SELB) last issued its earnings results on Thursday, May 9th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.06. The business had revenue of $0.01 million for the quarter. As a group, research analysts predict that Selecta Biosciences Inc will post -1.35 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Wasatch Advisors Inc. increased its position in Selecta Biosciences by 2,546.1% during the first quarter. Wasatch Advisors Inc. now owns 2,923,702 shares of the company’s stock worth $6,929,000 after buying an additional 2,813,212 shares during the period. Polaris Venture Management Co. V L.L.C. increased its position in Selecta Biosciences by 72.6% during the first quarter. Polaris Venture Management Co. V L.L.C. now owns 2,773,479 shares of the company’s stock worth $6,573,000 after buying an additional 1,166,666 shares during the period. Fosun International Ltd increased its position in Selecta Biosciences by 153.4% during the first quarter. Fosun International Ltd now owns 438,330 shares of the company’s stock worth $938,000 after buying an additional 265,330 shares during the period. FMR LLC increased its position in Selecta Biosciences by 23.5% during the fourth quarter. FMR LLC now owns 345,046 shares of the company’s stock worth $918,000 after buying an additional 65,623 shares during the period. Finally, Two Sigma Investments LP increased its position in Selecta Biosciences by 87.8% during the fourth quarter. Two Sigma Investments LP now owns 200,498 shares of the company’s stock worth $533,000 after buying an additional 93,719 shares during the period. 49.67% of the stock is currently owned by institutional investors and hedge funds.

Selecta Biosciences Company Profile (NASDAQ:SELB)

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.

See Also: Economic Reports

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.